Tempus AI Today
As of 04:00 PM ET
- 52 week range
- $22.89
▼
$79.49
- Price target
- $56.36
Shares of Tempus AI Inc. Nasdaq: TEM Its shares rose 35% on Tuesday, bringing its market value to $7.5 billion. The rise was driven by headline-grabbing news and strong market sentiment, underscoring the company’s leadership in integrating artificial intelligence (AI) into healthcare. Tempus, a precision medicine company, leverages artificial intelligence to deliver personalized care solutions and improve therapeutic development.
Pelosi’s investment attracts attention
On Tuesday, Tempus first caught investors’ attention following revelations of routine trading by former House Speaker Nancy Pelosi. On January 14, Pelosi purchased 50 call options on Tempus stock, expiring in January 2026, with a strike price of $20. At the time of trading, Tempus shares closed just under $32, but by Tuesday, the stock had risen to more than $47.
Pelosi’s deals are closely watched given her track record of well-timed investments, with her husband’s venture capital connections amplifying public and institutional interest. In addition to Tempus, Pelosi also disclosed positions in Vistra and Palo Alto Networks, both of which saw gains on Tuesday, contributing to the broader hype around her portfolio.
Game-changing launch: Olivia’s health app
The most important driver behind Tempus’ rise was the announcement of its new AI-powered health app, Olivia. Olivia is designed to serve as a personal health guardian, integrating patient data from more than 1,000 health systems and platforms like Apple Health and Google Fit. Olivia aims to change how patients manage their health by centralizing health records and providing AI-generated insights.
Among its notable features, the app’s Smart Profile Summary leverages artificial intelligence to compile patient data into a comprehensive health overview. The AI-powered note-taking software transcribes and summarizes doctor’s appointments to ensure clarity and accessibility for patients. Olivia also enables seamless sharing of medical images and health data, facilitating better communication between healthcare providers.
Eric Lefkofsky, founder and CEO of Tempus, highlighted Olivia as a key step in empowering patients to take control of their health journeys. Available on iOS and Android, Olivia underscores Tempus’ commitment to harnessing AI to drive better patient outcomes. Tuesday’s market enthusiasm reflects growing recognition of the transformative potential of artificial intelligence in healthcare.
Bullish market sentiment
Tempus AI stock forecast today
$56.36
11.72% upModerate purchase
Based on 12 analyst ratings
| High expectations | $74.00 |
|---|---|
| Average expectations | $56.36 |
| Low expectations | $44.00 |
Tempus AI stock forecast details
Aside from today’s news, sentiment around Tempus remains positive. Analysts have assigned a consensus Moderate Buy rating, with a price target indicating 18% upside potential. Institutional investors are also bullish, with a net $900 million flowing into the stock over the past 12 months compared to outflows of just $48.7 million. Cathie Wood’s ARK Investment Management owns a 1.5% stake in Tempus worth $135 million, boosting investor confidence.
Strong initial financial results
Tempus’ preliminary financials for the fourth quarter of 2024, announced on January 13, showed its growth trajectory. The company reported revenue of $200.55 million for the quarter, an increase of 35% year over year. While it reported a net loss of $75.84 million for the quarter, its EPS of -$0.25 beat expectations.
The company expects 2025 revenues to exceed $1.23 billion, driven by its genomics and data services sectors. Its acquisition of Ambry Genetics, scheduled to close by February 2025, is expected to expand its expertise in cancer screening, pediatrics, rare diseases and cardiology. This acquisition allows Tempus to strengthen its balance sheet and AI-powered data infrastructure, strengthening its leadership in precision medicine.
Institutional support fuels growth
The significant rise in institutional ownership has been a critical element of Tempus’ momentum. With prominent investors such as ARK and other institutions taking large positions, confidence in the company’s long-term potential is clear. The broader market recognizes the transformative role that AI plays in healthcare, and Tempus stands at the forefront of this innovation.
Tempus AI’s strategic moves and pioneering technology applications position it as a key player in the future of precision medicine, blending artificial intelligence and data analytics to reshape healthcare delivery.
Before you consider Tempus AI, you’ll want to hear this.
MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and Tempus AI wasn’t on the list.
While Tempus AI currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View the five stocks here
MarketBeat just released its list of 20 stocks that Wall Street analysts rate highly He hates. These companies may look like they have good fundamentals, but senior analysts smell something very rotten. Are any of these companies Latent About your wallet? Find out by clicking the link below.
